Completed
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
J1O-MC-JZHC - ClinicalTrials.gov - NCT03955939
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
How long will I be in the trial?
Your participation in this trial could last up to 23 months, depending on your cancer type and how you and your tumor respond.
Completed
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
J1O-MC-JZHC - ClinicalTrials.gov - NCT03955939
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
How long will I be in the trial?
Your participation in this trial could last up to 23 months, depending on your cancer type and how you and your tumor respond.
Key Requirements
Age :
18+
Sex:
Female
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
Female
Participants must
Participants must have hormone receptor positive and HER2 negative metastatic breast cancer
Participants must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor
Participants must be able and willing to undergo mandatory tumor biopsy
Participants must have normal organ function
Participants must be able to swallow capsules
Participants must NOT
Participants must not have had prior chemotherapy for metastatic breast cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
Participants must not be currently enrolled in a clinical study
Participants must not have another serious medical condition
Participants must not have previously received an aurora kinase inhibitor
Trial Summary
Conditions the trial is for
Metastatic Breast Cancer
What the trial is testing?
LY3295668 Erbumine, Endocrine therapy, Midazolam
Could I receive a Placebo?
no
Enrollment Goal
100
Trial Dates
August 2019 - May 2020
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
Female
Participants must
Participants must have hormone receptor positive and HER2 negative metastatic breast cancer
Participants must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor
Participants must be able and willing to undergo mandatory tumor biopsy
Participants must have normal organ function
Participants must be able to swallow capsules
Participants must NOT
Participants must not have had prior chemotherapy for metastatic breast cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
Participants must not be currently enrolled in a clinical study
Participants must not have another serious medical condition
Participants must not have previously received an aurora kinase inhibitor
Trial Summary
Conditions the trial is for
Metastatic Breast Cancer
What the trial is testing?
LY3295668 Erbumine, Endocrine therapy, Midazolam
Could I receive a Placebo?
no
Enrollment Goal
100
Trial Dates
August 2019 - May 2020
Trial Phase
1
Not the right fit? Sign up to receive updates on new Metastatic Breast Cancer trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Metastatic Breast Cancer Resources
